ليتروزول تيڤع

البلد: إسرائيل

اللغة: العربية

المصدر: Ministry of Health

العنصر النشط:

LETROZOLE 2.5 MG

متاح من:

TEVA PHARMACEUTICAL INDUST.LTD

ATC رمز:

L02BG04

الشكل الصيدلاني:

TABLETS

طريقة التعاطي:

PER OS

المصنعة من قبل:

TEVA PHARMACEUTICAL INDUSTRIES LTD

المجموعة العلاجية:

LETROZOLE

الخصائص العلاجية:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

تاريخ الترخيص:

2010-01-01